Rnaz stock forecast.
Each share of common stock (or Pre-Funded Warrant) is being sold at a public offering price of $0.51 per share (inclusive of the Pre-Funded Warrant exercise price of $0.01).
The RNAZ stock price is -10536.36% off its 52-week high price of $23.40 and 31.82% above the 52-week low of $0.15. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.59 million shares traded. The 3-month trading volume is 6.95 million shares. The consensus among analysts is that TransCode Therapeutics ...TransCode Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. RNAZ updated stock price target summary.RNAZ stock forecast . Since RNAZ is a newly listed company with a market cap of only about $50 million, none of the analysts are covering the stock. The forecast for RNAZ will eventually depend on ...Find real-time VTGN - Vistagen Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.Nov 1, 2023 · According to analyst projections, RNAZ’s forecast low is $3.00 with $3.00 as the target high. To hit the forecast high, the stock’s price needs a -733.33% plunge from its current level, while the stock would need to soar -733.33% for it to hit the projected low. TransCode Therapeutics Inc (RNAZ) estimates and forecasts
Nov 1, 2021 · Novavax (NVAX) stock forecast: Targets for 2022, 2025 and 2027. Algorithm-based NVAX stock forecast from Wallet Investor (as of 20 January) estimated the price to reach $189.77 by the end of 2022, $268.69 by the end of 2023 and to hit $435.51 by the end of 2025. Although the service did not provide targets for 2030, its 5-year Novevax share ... RNAZ: TransCode Therapeutics - Price and Consensus Chart. Get the latest Price and Consensus Chart for TransCode Therapeutics from Zacks Investment ResearchOverview TransCode Therapeutics, Inc. (RNAZ), listed on NASDAQ, engages in the development of innovative health solutions. As of October 13, 2023…
RNAZ stock, also known as Transcode Therapeutics Inc, has shown promising performances on October 31, 2023, according to data provided by CNN Money. The stock has garnered attention from analysts, who have offered positive price forecasts for the next 12 months. The one analyst providing price forecasts for RNAZ stock has a median target of $3. ...Feb 15, 2023 · RNAZ stock has been on a downward trend ever since announcing its proposed public stock offering at the start of the month. With today’s news, the company’s shares are up 100.5% in pre-market ...
Nov 29, 2023 · TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including ... 1 analysts have issued 1 year target prices for TransCode Therapeutics' stock. Their RNAZ share price targets range from $12.00 to $12.00. On average, they expect the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 5,379.5% from the stock's current price.The 36-month beta value for RNAZ is also noteworthy at -0.11. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”. The average price estimated by analysts for RNAZ is $3.00, which is $2.7 above than the current price.RNAz is a program for predicting structurally conserved and thermodynamically stable RNA secondary structures in multiple sequence alignments. It can be used in genome wide screens to detect functional RNA structures, as found in noncoding RNAs and cis-acting regulatory elements of mRNAs. The method is described in:
TransCode Therapeutics (RNAZ) will release its next earnings report on Nov 13, 2023. In the last quarter TransCode Therapeutics reported -$3.29 EPS in relation to -$3.29 expected by the market.
While only two analysts cover RNAZ stock according to TipRanks, they are incredibly bullish on its prospects. Both experts forecast shares hitting $12 , translating to over 400% upside, even with ...
Predicting the weather has long been one of life’s great mysteries — at least for regular folks. Over the years, you’ve probably encountered a few older adults — maybe even your own grandparents — who made some weather predictions based on ...The U.S. National Weather Service (NWS) is a part of the National Oceanic and Atmospheric Administration (NOAA). Many people rely on the National Weather Service’s forecasts in order to better anticipate what the weather will be like so the...Forecast Changes; Commodities. Gold; Copper; Crude Oil; ... TransCode Therapeutics, Inc. Common Stock (RNAZ) Nasdaq Listed; Nasdaq 100; ... RNAZ RNAZ AFTER HOURS QUOTE RNAZ LATEST AFTER HOURS TRADES.On Tuesday, TransCode Therapeutics Inc [NASDAQ:RNAZ] saw its stock jump 3.09% to $0.24. On the same session, the stock had its day’s lowest price of $0.2144, but rose to a high of $0.24. Over the last five days, the stock has gained 4.80%. TransCode Therapeutics Inc shares have fallen nearly -98.22% since the year began.The Salarius Pharmaceuticals Inc. stock price gained 0.362% on the last trading day (Wednesday, 29th Nov 2023), rising from $0.690 to $0.693. During the last trading day the stock fluctuated 4.48% from a day low at $0.670 to a day high of $0.700. The price has fallen in 6 of the last 10 days and is down by -6.37% for this period.
Nov 22, 2023 · Summit Therapeutics Inc. (NASDAQ:SMMT) issued its earnings results on Monday, November, 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.09. The firm earned $6.12 million during the quarter. Transcode Therapeutics Inc (RNAZ) Stock Price & News - Google Finance Home RNAZ • NASDAQ Transcode Therapeutics Inc Follow Share $0.24 Nov 27, 3:06:29 AM GMT-5 · USD · NASDAQ · Disclaimer...People use statistics daily for weather forecasts, predicting disease, preparing for emergencies, medical research, political campaigns, tracking sales, genetics, insurance, the stock market and quality testing.6 Wall Street research analysts have issued 12-month target prices for Avidity Biosciences' shares. Their RNA share price targets range from $20.00 to $71.00. On average, they expect the company's share price to reach $38.17 in the next twelve months. This suggests a possible upside of 371.2% from the stock's current price.Find real-time RNAZ - Transcode Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.Find real-time PHXM - Phaxiam Therapeutics SA stock quotes, company profile, news and forecasts from CNN Business.The price of RNAZ leaped by -41.10% over the last 30 days. And in the last five days, it has fallen by -8.71%. Currently, the stock price of TransCode Therapeutics Inc (RNAZ) is $0.22. In the most recent trading session, the stock underwent a significant upswing, peaking at $0.245 after opening at $0.2335.
BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using …TransCode Therapeutics Stock Down 9.5 %. RNAZ stock opened at $0.26 on Friday. TransCode Therapeutics has a 12 month low of $0.25 and a 12 month high of $23.40. The firm’s 50-day moving average ...
Earnings for TransCode Therapeutics are expected to grow in the coming year, from ($5.57) to ($0.63) per share. TransCode Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, March 29th, 2024 based off prior year's report dates. Read More.On May 22, 2023, Transcode Therapeutics Inc’s stock (RNAZ) experienced a significant increase in value following the release of positive news regarding the company’s future prospects. According to CNN Money, the one analyst offering a 12-month price forecast for RNAZ had a median target of $6.00, with a high estimate of $6.00 and a low estimate of …Track TransCode Therapeutics Inc (RNAZ) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Analyst Forecast. According to one analyst, the rating for RNAZ stock is "Strong Buy" and the 12-month stock price forecast is $3.0.finanznachrichten.de - September 30 at 12:13 AM. TransCode Therapeutics Announces Closing of $8.5 Million Public Offering. finance.yahoo.com - September 28 at 6:53 PM. Why Transcode Therapeutics (RNAZ) Stock Is Down Nearly 70%. benzinga.com - September 26 at 2:06 PM.View TransCode Therapeutics Inc RNAZ investment & stock information. Get the latest TransCode Therapeutics Inc RNAZ detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.TransCode Therapeutics (NASDAQ: RNAZ ) stock is rallying higher on Wednesday after the company withdrew plans for a secondary offering. According to the company, it won't pursue a plan to sell 12.5 million shares in a public offering.Find the latest Earnings Report Date for TransCode Therapeutics, Inc. Common Stock (RNAZ) at Nasdaq.com.BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using …TransCode Therapeutics Inc (RNAZ) shares are -94.37% down over the last 6 months, with its year-to-date growth rate higher than industry average at 80.07% against 10.60%. Revenue is forecast to grow 84.90% this quarter before jumping 85.80% for the next one. RNAZ Dividends. TransCode Therapeutics Inc has its next earnings report out …
RNAZ : 0.2620 (+0.77%) Positive Results Causes Pop In Biotech Stock Yolowire - Wed Oct 26, 2022. A Boston-based %Biotech company really captured the attention of traders on Wednesday after the it reported Positive Preclinical Results with its Lead Candidate, TTX-MC138, in Pancreatic Adenocarcinoma....
NASDAQ:FSRDQ - Fast Radius Stock Price, News & Analysis. DOW 35,390.15. QQQ 389.51. Turned down for a loan, business owners look to family and even crowdsourcing to get money to grow. Important info on NVDA trade (Ad) 12 crew members are missing, 1 dead after a cargo ship sinks off a Greek island in stormy seas.
Should I buy Transcode Therapeutics (RNAZ)? Use the Zacks Rank and Style Scores to find out is RNAZ is right for your portfolio.RNAZ stock is down 25.2% as of Friday morning and is down 96.8% year-to-date as of yesterday’s close. Investors seeking out even more of the most recent stock market news for Friday will want to ...Dec 1, 2023 · 6 Wall Street research analysts have issued 12-month target prices for Avidity Biosciences' shares. Their RNA share price targets range from $20.00 to $71.00. On average, they expect the company's share price to reach $38.17 in the next twelve months. This suggests a possible upside of 371.2% from the stock's current price. Vallon Pharmaceuticals' stock was trading at $8.70 on January 1st, 2023. Since then, VLON shares have decreased by 93.0% and is now trading at $0.6080. View the best growth stocks for 2023 here.TransCode Therapeutics Inc (NASDAQ: RNAZ)’s stock price has increased by 3.75 compared to its previous closing price of 0.24. However, the company has seen a 8.07% increase in its stock price over the last five trading sessions. InvestorPlace reported 2023-10-27 that TransCode Therapeutics (NASDAQ: RNAZ ) stock is taking a beating …Track TransCode Therapeutics Inc (RNAZ) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get …Nov 16, 2023 · It follows that stock’s current price would drop -934.48% in reaching the projected high whereas dropping to the targeted low would mean a loss of -934.48% for stock’s current value. TransCode Therapeutics Inc (RNAZ) estimates and forecasts The stock’s price-to-sales ratio is 0.32, and the price-to-book ratio is 0.28. The P/E ratio for APRN is currently not available (NM). ... 2023, with an EPS forecast of -$0.75 for the quarter. The company had an annual revenue of $470.4M and an annual loss of $88.4M last year, with a net profit margin of -18.79%.Quick Take. TransCode Therapeutics ( NASDAQ: RNAZ) intends to raise $25 million from the sale of its common stock in an IPO, according to an amended registration statement. The company is ...TransCode Therapeutics Stock Down 9.5 %. RNAZ stock opened at $0.26 on Friday. TransCode Therapeutics has a 12 month low of $0.25 and a 12 month high of $23.40. The firm’s 50-day moving average ...Ideas Financials Technicals Forecast . RNAZ news flow. Love in every #TradingView. 50M+ ... Stock Screener Forex Screener Crypto Pairs Screener Crypto Coins Screener Stock ... Find the latest TransCode Therapeutics, Inc. financial news and headlines to keep up with the events that impact RNAZ performance.
Get the latest Connexa Sports Technologies Inc (CNXA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Nov 29, 2023 · TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including ... View the latest TransCode Therapeutics Inc. (RNAZ) stock price, news, historical charts, analyst ratings and financial information from WSJ.TransCode Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. RNAZ updated stock price target summary. Instagram:https://instagram. sales and business development trainingticker aiewa etflithium batteries stock While only two analysts cover RNAZ stock according to TipRanks, they are incredibly bullish on its prospects. Both experts forecast shares hitting $12 , translating to over 400% upside, even with ... beta in stocks meaningoilu stock price Stock Price Forecast. There is no forecast data available. Chart unavailable. Analyst Recommendations. There are no recommendations available. Earnings and Sales Forecasts. Current Quarter.We've seen plenty of personal finance tools designed to help you track what you're spending, but web site PocketSmith is an impressive new web-based personal finance tool with an emphasis on forecasting your financial future. We've seen ple... top 100 esg companies Nov 1, 2023 · According to analyst projections, RNAZ’s forecast low is $3.00 with $3.00 as the target high. To hit the forecast high, the stock’s price needs a -733.33% plunge from its current level, while the stock would need to soar -733.33% for it to hit the projected low. TransCode Therapeutics Inc (RNAZ) estimates and forecasts Nov 24, 2023 · Stock analysis for TransCode Therapeutics Inc (RNAZ:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.